Relais Q3 adjusted EBITA of EUR 10.9m was up 19% y/y and came 5% below LSEG Data & Analytics consens...
* 2% sales beat & adj. EBIT SEK 45m vs. ABGSCe 29m * Announces restructuring programme of SEK 20m p.
Q3 report on Thursday, 23 October at 12:00 CET* '25e-'27e adj.
Redeye has updated its estimates following Physitrack’s Q3 2025 report, which was broadly in line wi...
Redeye updates its Base Case and forecasts for Lime following the Q3 report.
Redeye leaves a short comment on Xspray following today's news that the FDA has accepted its NDA for...
* Acquires NetApp partner Consular for DKK 65m, adds 3% to sales, 7% to EBITA * 4.
* Sales SEK 14m vs. ABGSCe 10m, EBIT in line at SEK -12m * No machine deliveries in the quarter (in ...
Redeye sees a solid report from Lime. While the numbers were slightly below our expectations, the ye...
Redeye provides an update following Q-linea’s Q3 2025 report.
Redeye is positive about the updated data from Paxman’s CIPN clinical trial in Singapore.
Following Suominen's profit warning on 15 October, we cut our estimates, which results in a slightly...
* Seasonally weaker volumes to weigh on earnings * 10-12% '26e-'27e sales growth, 21-22% EBIT margin...
Redeye comments on Active Biotech’s proposed fully guaranteed rights issue of SEK70m, which is large...
YIT reports its Q3 results on October 30th. The quarter is expected to be quite slow, with housing u...
